Bi-allelic Missense Pathogenic Variants in TRIP13 Cause Female Infertility Characterized by Oocyte Maturation Arrest.


Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
02 07 2020
Historique:
received: 03 02 2020
accepted: 30 04 2020
pubmed: 31 5 2020
medline: 21 10 2020
entrez: 31 5 2020
Statut: ppublish

Résumé

Normal oocyte meiosis is a prerequisite for successful human reproduction, and abnormalities in the process will result in infertility. In 2016, we identified mutations in TUBB8 as responsible for human oocyte meiotic arrest. However, the underlying genetic factors for most affected individuals remain unknown. TRIP13, encoding an AAA-ATPase, is a key component of the spindle assembly checkpoint, and recurrent homozygous nonsense variants and a splicing variant in TRIP13 are reported to cause Wilms tumors in children. In this study, we identified homozygous and compound heterozygous missense pathogenic variants in TRIP13 responsible for female infertility mainly characterized by oocyte meiotic arrest in five individuals from four independent families. Individuals from three families suffered from oocyte maturation arrest, whereas the individual from the fourth family had abnormal zygote cleavage. All displayed only the infertility phenotype without Wilms tumors or any other abnormalities. In vitro and in vivo studies showed that the identified variants reduced the protein abundance of TRIP13 and caused its downstream molecule, HORMAD2, to accumulate in HeLa cells and in proband-derived lymphoblastoid cells. The chromosome mis-segregation assay showed that variants did not have any effects on mitosis. Injecting TRIP13 cRNA into oocytes from one affected individual was able to rescue the phenotype, which has implications for future therapeutic treatments. This study reports pathogenic variants in TRIP13 responsible for oocyte meiotic arrest, and it highlights the pivotal but different roles of TRIP13 in meiosis and mitosis. These findings also indicate that different dosage effects of mutant TRIP13 might result in two distinct human diseases.

Identifiants

pubmed: 32473092
pii: S0002-9297(20)30148-8
doi: 10.1016/j.ajhg.2020.05.001
pmc: PMC7332649
pii:
doi:

Substances chimiques

Cell Cycle Proteins 0
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-
TRIP13 protein, human EC 3.6.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-23

Informations de copyright

Copyright © 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

J Med Genet. 2019 Jul;56(7):471-480
pubmed: 30877238
Nat Genet. 2017 Jul;49(7):1148-1151
pubmed: 28553959
PLoS Genet. 2009 Oct;5(10):e1000702
pubmed: 19851446
Am J Hum Genet. 2017 Oct 5;101(4):609-615
pubmed: 28965849
Nat Commun. 2017 Dec 5;8(1):1956
pubmed: 29208896
Reproduction. 2005 Dec;130(6):791-9
pubmed: 16322539
Nature. 2018 Jul;559(7713):274-278
pubmed: 29973720
PLoS Genet. 2010 Aug 12;6(8):
pubmed: 20711356
Am J Hum Genet. 2018 Apr 5;102(4):649-657
pubmed: 29606300
Curr Top Pathol. 1976;62:9-27
pubmed: 1009793
Nat Genet. 2002 Apr;30(4):446-9
pubmed: 11912493
J Biol Chem. 2014 Aug 22;289(34):23928-37
pubmed: 25012665
Mol Cell. 2017 Sep 21;67(6):1026-1036.e2
pubmed: 28844861
Eur J Hum Genet. 2019 Feb;27(2):300-307
pubmed: 30297906
PLoS Genet. 2007 Aug;3(8):e130
pubmed: 17696610
Science. 2012 Mar 23;335(6075):1496-9
pubmed: 22442484
Semin Cell Dev Biol. 2015 Sep;45:68-76
pubmed: 26454098
PLoS Genet. 2015 Mar 13;11(3):e1005017
pubmed: 25768017
EMBO Mol Med. 2018 May;10(5):
pubmed: 29661911
Gynecol Endocrinol. 2018 Oct;34(10):900-904
pubmed: 29671363
Biochim Biophys Acta. 1975 Dec 18;410(2):310-7
pubmed: 1092
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
EMBO J. 2017 Aug 15;36(16):2419-2434
pubmed: 28659378
Nat Rev Genet. 2013 Nov;14(11):794-806
pubmed: 24136506
Cell Rep. 2016 Feb 9;14(5):1086-1099
pubmed: 26832417
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11536-40
pubmed: 26324890
Am J Hum Genet. 2016 Sep 1;99(3):744-752
pubmed: 27545678
Hum Reprod. 2018 Jun 1;33(6):1183-1190
pubmed: 29697801
N Engl J Med. 2016 Jan 21;374(3):223-32
pubmed: 26789871
J Gen Virol. 2019 May;100(5):851-862
pubmed: 30907723
Mol Cell Endocrinol. 2014 Jan 25;382(1):480-487
pubmed: 23916417
Nat Cell Biol. 2020 Jan;22(1):87-96
pubmed: 31915374
Genome Biol. 2015 Nov 05;16:240
pubmed: 26537248
J Assist Reprod Genet. 2018 Jul;35(7):1349-1356
pubmed: 29704226
Hum Reprod. 2017 Feb;32(2):457-464
pubmed: 27989988

Auteurs

Zhihua Zhang (Z)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Bin Li (B)

Reproductive Medicine Center, Shanghai Ninth Hospital, Shanghai Jiao Tong University, Shanghai 200011, China.

Jing Fu (J)

Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.

Rong Li (R)

Reproductive Medicine Center, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China.

Feiyang Diao (F)

The State Key Laboratory of Reproductive Medicine, Clinical Center of Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.

Caihong Li (C)

Assisted Reproductive Technology Laboratory, Shenyang Jinghua Hospitals, Shenyang, Liaoning 110005, China.

Biaobang Chen (B)

National Health Commission Key Lab of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China.

Jing Du (J)

National Health Commission Key Lab of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China.

Zhou Zhou (Z)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Jian Mu (J)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Zheng Yan (Z)

Reproductive Medicine Center, Shanghai Ninth Hospital, Shanghai Jiao Tong University, Shanghai 200011, China.

Ling Wu (L)

Reproductive Medicine Center, Shanghai Ninth Hospital, Shanghai Jiao Tong University, Shanghai 200011, China.

Shuai Liu (S)

Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.

Wenjing Wang (W)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Lin Zhao (L)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Jie Dong (J)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.

Lin He (L)

Bio-X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai 200030, China.

Xiaozhen Liang (X)

Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.

Yanping Kuang (Y)

Reproductive Medicine Center, Shanghai Ninth Hospital, Shanghai Jiao Tong University, Shanghai 200011, China.

Xiaoxi Sun (X)

Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.

Qing Sang (Q)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China. Electronic address: sangqing@fudan.edu.cn.

Lei Wang (L)

Institute of Pediatrics, Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, the Ministry of Science and Technology, the Institutes of Biomedical Sciences, and the State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China; Shanghai Center for Women and Children's Health, Shanghai 200062, China. Electronic address: wangleiwanglei@fudan.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH